Li Mao, Yu Bin, Zhang Xiaoli, Pan Jia, Tang Lei, Zhang Yi, Wang Ruixin, Zeng Honglian, Yang Shujuan
Department of Health Management Centre, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, China.
West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Med (Lausanne). 2025 Apr 28;12:1572853. doi: 10.3389/fmed.2025.1572853. eCollection 2025.
The impact of moderate drinking on the risk of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) remains controversial worldwide. Notably, China, with the fastest-growing incidence of NAFLD and the highest number of alcohol-attributable deaths globally, has relatively few studies addressing this issue. This study aimed to explore the association between alcohol consumption and liver fibrosis in Chinese men with metabolic dysfunction-associated steatotic liver disease (MASLD).
We recruited 4,683 male employees diagnosed with MASLD from southwest China, including 4,287 with pure MASLD and 396 with metabolic and alcohol-related liver disease (MetALD) who consumed increased alcohol (30-60 g/d). Advanced fibrosis was defined as a fibrosis-4 index (FIB-4) ≥ 2.67, and FIB-4 ≥ 1.30 indicated an intermediate/high probability of hepatic fibrosis. Logistic regression models were used to assess the association between alcohol consumption and hepatic fibrosis, and analyze the modification effect of body mass index (BMI) and waist-to-hip ratio (WHR) on the association. Propensity score matching method was used to test the robustness of the regression results.
Compared with non-drinkers, both moderate (OR = 3.02, 95% CI: 1.16-10.31) and increased alcohol consumption (OR = 4.64, 95% CI: 1.60-16.82) were significantly associated with an increased risk of advanced fibrosis in males with MASLD. Additionally, moderate (OR = 1.33, 95% CI: 1.07-1.66) and increased drinking (OR = 1.74, 95% CI: 1.28-2.34) were associated with intermediate/high probability of hepatic fibrosis, with similar results from logistic regression analysis in propensity score-matched cases. Trend analysis revealed the risk of hepatic fibrosis increased with increasing alcohol intake (FIB-4 ≥ 1.30, for trend < 0.001; FIB-4 ≥ 2.67, for trend = 0.007). Further subgroup analysis showed that the association between moderate drinking and intermediate/high probability of hepatic fibrosis was predominantly observed in males with BMI ≥ 23 kg/m (OR = 1.35, 95% CI: 1.08-1.69) and those with WHR ≥ 0.9 (OR = 1.40, 95% CI: 1.11-1.78).
In China, moderate alcohol intake may heighten the risk of hepatic fibrosis in males with MASLD who are overweight/obese or have abdominal obesity. Moreover, males with MetALD may have a higher risk of fibrosis compared to those with pure MASLD.
在全球范围内,适度饮酒对非酒精性脂肪性肝病(NAFLD)患者肝纤维化风险的影响仍存在争议。值得注意的是,中国NAFLD发病率增长最快,且全球酒精所致死亡人数最多,但针对这一问题的研究相对较少。本研究旨在探讨中国患有代谢功能障碍相关脂肪性肝病(MASLD)男性的饮酒量与肝纤维化之间的关联。
我们招募了来自中国西南部的4683名被诊断为MASLD的男性员工,其中包括4287例单纯MASLD患者和396例代谢性和酒精性相关肝病(MetALD)患者,这些患者饮酒量增加(30 - 60克/天)。将晚期纤维化定义为纤维化-4指数(FIB-4)≥2.67,FIB-4≥1.30表明肝纤维化的可能性为中度/高度。采用逻辑回归模型评估饮酒量与肝纤维化之间的关联,并分析体重指数(BMI)和腰臀比(WHR)对该关联的修正作用。采用倾向评分匹配法检验回归结果的稳健性。
与不饮酒者相比,适度饮酒(OR = 3.02,95%CI:1.16 - 10.31)和饮酒量增加(OR = 4.64,95%CI:1.60 - 16.82)均与MASLD男性患者晚期纤维化风险增加显著相关。此外,适度饮酒(OR = 1.33,95%CI:1.07 - 1.66)和饮酒量增加(OR = 1.74,95%CI:1.28 - 2.34)与肝纤维化的中度/高度可能性相关,倾向评分匹配病例的逻辑回归分析结果相似。趋势分析显示,肝纤维化风险随饮酒量增加而增加(FIB-4≥1.30,趋势P<0.001;FIB-4≥2.67,趋势P = 0.007)。进一步亚组分析表明,适度饮酒与肝纤维化中度/高度可能性之间的关联主要见于BMI≥23kg/m²的男性(OR = 1.35,95%CI:1.08 - 1.69)和WHR≥0.9的男性(OR = 1.40,95%CI:1.11 - 1.78)。
在中国,适度饮酒可能会增加超重/肥胖或有腹型肥胖的MASLD男性患者的肝纤维化风险。此外,与单纯MASLD患者相比,MetALD男性患者的纤维化风险可能更高。